Calcium Channel Blockers in Hypertension

Hypertension: A Companion to Braunwald's Heart Disease: Second Edition

Volumn , Issue , 2013, Pages 204-218

  Zanchetti, Alberto ^a,b  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880358666     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2766-1.00022-3     Document Type: Chapter

References (90)

1. Triggle D.J. Mechanisms of action of calcium channel antagonists. Calcium Antagonists in Clinical Medicine 2002, 1-32. Hanley & Belfus, Philadelphia, PA. 3rd ed. M. Epstein (Ed.).
2. Godfraind T. Calcium Channel Blockers 2004, Birkhäuser, Basel, Switzerland.
3. Perez-Reyes E. Molecular physiology of low-voltage activated t-type calcium channels. Physiol Rev 2003, 83:117-161.
4. Ertel E.A., Campbell K.P., Harpold M.M., et al. Nomenclature of voltage-gated calcium channels. Neuron 2000, 25:233-235.
5. Meredith P.A., Elliott H.L. Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. J Hypertens 2004, 22:1641-1648.
6. Leonetti G., Sala C., Bianchini C., et al. Antihypertensive and renal effects of oral administration of verapamil. Eur J Clin Pharmacol 1980, 18:375-382.
7. Olivari M.T., Bartorelli C., Polese A., et al. Treatment of hypertension with nifedipine, a calcium antagonist agent. Circulation 1979, 59:1056-1062.
8. Wald D.S., Law M., Morris J.K., et al. Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials. Am J Med 2009, 122:290-300.
9. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003, 289:2560-2572.
10. Mancia G., De Backer G., Dominiczak A., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
11. World Health Organization-International Society of Hypertension statement on management of hypertension. J Hypertens 2003, 21:1983-1992. World Health Organization-International Society of Hypertension Writing Group.
12. Sanchez R.A., Ayala M., Baglivo H., et al. Latin American guidelines on hypertension. J Hypertens 2009, 27:905-922.
13. Ogihara T., Kikuchi K., Matsuoka H., et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009, 32:3-107.
14. National Institute for Health and Clinical Excellence (NICE) Hypertension. The clinical management of primary hypertension in adults. Clinical Guideline 2011, 127. Accessed August 2011. http://www.nice.org.uk/guidance/CG127.
15. Brewster L.M., van Montfrans G.A., Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004, 141:614-627.
16. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008, 336:1121-1123. Blood Pressure Lowering Treatment Trialists' Collaboration.
17. Lund-Johansen P. Hemodynamic effects of calcium antagonists in hypertension. Calcium Antagonists in Clinical Medicine 2002, 315-335. Hanley & Belfus, Philadelphia, PA. 3rd ed. M. Epstein (Ed.).
18. Gong L., Zhang W., Zhu Y., et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996, 14:1237-1245.
19. Staessen J., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension in Europe. Lancet 1997, 350:757-764.
20. Liu L., Wang J.G., Gong L., et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension (Syst-China). J Hypertens 1998, 16:1823-1829.
21. Lubsen J., Wagener G., Kirwan B.-A., et al. Effects of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005, 23:641-648.
22. Nissen S.E., Turzcu E.M., Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: A randomized controlled trial. JAMA 2004, 292:2217-2226.
23. Liu L., Zhang Y., Liu G., et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005, 23:2157-2172.
24. Hansson L., Lindholm L., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
25. Randomized double-blind comparison of a calcium-antagonist and a diuretic in elderly hypertensives. Hypertension 1999, 34:1129-1133. National Intervention Cooperative Study in Elderly Hypertensives Study Group.
26. Hansson L., Hedner T., Lund-Johansen P., et al. Randomised trial of effects of calcium-antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
27. Brown M., Palmer C., Castaigne A., et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366-372.
28. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002, 288:2981-2997.
29. Black H.R., Elliott W.J., Grandis G., et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA 2003, 289:2073-2082.
30. Malacco E., Mancia G., Rappelli A., et al. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 2003, 12:160-167. for the SHELL Investigators.
31. Pepine C.J., Handberg E.M., Cooper-De Hoff R.M., et al. A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805-2819.
32. Dahlöf B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005, 366:895-906.
33. Yui Y., Sumiyoshi T., Kodama K., et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Disease-B (JMIC-B) randomized trial. Hypertens Res 2004, 27:181-191.
34. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004, 363:2022-2031.
35. Schrader J., Luders S., Kulschewski A., et al. Morbidity and Mortality after Stroke. Eprosartan compared with nitrendipine for Secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005, 36:1218-1226.
36. Furberg C., Psaty B., Meyer J. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995, 92:1325-1331.
37. Mancia G., Laurent S., Agabiti-Rosei E., et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009, 27:2121-2158.
38. Zhang Y., Zhang X., Liu L., Zanchetti A., et al. Is a SBP target below 140 mm Hg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J 2011, 32:1500-1508.
39. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003, 362:1527-1535. Blood Pressure Lowering Treatment Trialists' Collaboration.
40. Costanzo P., Perrone-Filardi P., Petretta M., et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. J Hypertens 2009, 27:1136-1151.
41. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:1665-1683.
42. Zanchetti A. Evidence-based medicine in hypertension: what type of evidence?. J Hypertens 2005, 23:1113-1120.
43. Webb A.J., Fischer U., Mehta Z., Rothwell P.M. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010, 375:906-915.
44. Rothwell P.M., Howard S.C., Dolan E., et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010, 375:895-905.
45. Hansson L., Zanchetti A., Carruthers S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
46. Agabiti-Rosei E., Dal Palù C., Leonetti G., et al. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hypertens 1997, 15:1337-1344. for the VHAS Investigators.
47. Leonetti G., Magnani B., Pessina A.C., et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002, 15:932-940.
48. Zanchetti A., Omboni S., La Commare P., et al. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol 2001, 38:642-650.
49. Pahor M., Guralnik J., Ferrucci L., et al. Calcium channel blockade and incidence of cancer in aged populations. Lancet 1996, 348:493-497.
50. Pahor M., Guralnik J., Furberg C., et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996, 347:1061-1065.
51. Coleman C.I., Baker W.L., Kluger J., White C.M. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 2008, 26:622-629.
52. Zanchetti A., Bond M., Hennig M., et al. Calcium-antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Circulation 2002, 106:2422-2427.
53. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201-207. Errata: 1518.
54. Zanchetti A., Hennig M., Baurecht H., et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens 2007, 25:2463-2470.
55. Epstein M., Waeber B. Fixed-dose combination therapy with calcium antagonists. Calcium Antagonists in Clinical Medicine 2002, 713-730. Hanley & Belfus, Philadelphia, PA. 3rd ed. M. Epstein (Ed.).
56. Wassertheil-Smoller S., Psaty B., Greenland P., et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA 2004, 292:2849-2859.
57. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428.
58. 2+ channel subtypes and pharmacology in the kidney. Circ Res 2007, 100:342-353.
59. Leonetti G., Gradnik R., Terzoli L., et al. Effect of single and repeated doses of the calcium antagonist felodipine on blood pressure, renal function, electrolytes and water balance, and renin-angiotensin-aldosterone system in hypertensive patients. J Cardiovasc Pharmacol 1986, 8:1243-1248.
60. Voyaki S.M., Staessen J.A., Thijs L., et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 2001, 19:511-519.
61. Rahman M., Pressel S., Davis B.R., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs. a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165:936-946.
62. Ruilope L.M., Zanchetti A., Julius S., et al. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens 2007, 25:1473-1479.
63. Wright J.T., Bakris G.L., Green T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 2002, 288:2421-2431.
64. Lewis E., Hunsicker L., Clarke W., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001, 345:851-860.
65. Ruggenenti P., Fassi A., Ilieva A.P., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1956.
66. Schrier R., Estacio R., Esler A., et al. Effect of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086-1097.
67. Estacio R.O., Jeffers B.W., Gifford N., Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23(suppl 2):B54-B64.
68. Weir M.R. The clinical utility of calcium antagonists in renal transplant recipients. Calcium Antagonists in Clinical Medicine 2002, 603-628. Hanley & Belfus, Philadelphia, PA. 3rd ed. M. Epstein (Ed.).
69. Zanchetti A., Hennig M., Hollweck R., et al. Baseline values but not treatment induced changes in carotid intima media thickness predict incident cardiovascular events in treated hypertensives. Findings in the ELSA. Circulation 2009, 120:1084-1090.
70. Pitt B., Byington R., Furberg C., et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000, 102:1503-1510.
71. Borhani N.O., Mercuri M., Borhani P.A., et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996, 276:785-791.
72. Zanchetti A., Agabiti-Rosei E., Dal Palù C., et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomised treatment with either verapamil or chlorthalidone on intima-media thickness. J Hypertens 1998, 16:1667-1676.
73. Simon A., Gariépy J., Moyse D., et al. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001, 103:2949-2954.
74. Motro M., Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001, 37:1410-1413.
75. Klingbeil A.U., Schneider M., Martus P., et al. A meta-analysis of the effects of treatment on LV mass in essential hypertension. Am J Med 2003, 115:41-46.
76. Tepstra W.L., May J.F., Smith A.J., et al. Long-term effects of amlodipine and lisinopril on LV mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001, 19:303-309.
77. Devereux R.B., Palmieri V., Sharpe N., et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on LV hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001, 104:1248-1254.
78. Zanchetti A., Ruilope L.M., Cuspidi C., et al. Comparative effects of the ACE inhibitor fosinopril and the calcium antagonist amlodipine on LV hypertrophy and urinary albumin excretion in hypertensive patients. Results of FOAM, a multicenter European study [abstract]. J Hypertens 2001, 19(suppl. 2):S92.
79. Agabiti-Rosei E., Trimarco B., Muiesan M.L., et al. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2005, 23:1091-1098. on behalf of the ELSA echocardiographic substudy group.
80. London G.M., Safar M.E. Arterial compliance and effect of calcium antagonists. Calcium Antagonists in Clinical Medicine 2003, 345-362. Hanley & Belfus, Philadelphia, PA. 3rd ed. M. Epstein (Ed.).
81. Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
82. Mackenzie I.S., McEniery C.M., Dhakam Z. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009, 54:409-413.
83. Watfa G., Rossignol P., Kearney-Schwartz A., et al. Use of calcium channel blockers is associated with better cognitive performance in older hypertensive patients with subjective memory complaints. J Hypertens 2010, 28:2485-2493.
84. Forette F., Seux M.L., Staessen J.A., et al. The prevention of dementia with hypertensive treatment. New evidence from the Systolic Hypertension in Europe (Syst-Eur) Study. Arch Intern Med 2002, 162:2046-2052.
85. Magee L.A., Cham C., Waterman E.J., et al. Hydralazine for treatment of severe hypertension in pregnancy: Meta-analysis. BMJ 2003, 327:1-10.
86. Packer M., O'Connor C.M., Ghali J.K., et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine in Survival Evaluation Study Group. N Engl J Med 1996, 335:1107-1114.
87. Cabell C.H., Trichon B.H., Valzquez E.J., et al. Importance of echocardiography in patients with severe nonischemic heart failure: The second Prospective Randomized Amlodipine in Survival Evaluation (PRAISE-2) echocardiographic study. Am Heart J 2004, 147:151-157.
88. Turnbull F., Neal B., Algert C., et al. Effect of different blood pressure lowering regimens on major cardiovascular events in individuals with and without diabetes: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005, 165:1410-1419. for the Blood Pressure Lowering Treatment Trialists' Collaboration.
89. Bakris G.L., Gaxiola E., Messerli F.H., et al. Clinical outcomes in the diabetes cohort of the International Verapamil SR-Trandolapril Study. Hypertension 2004, 44:637-642.
90. Zanchetti A., Julius S., Kjeldsen S., et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006, 24:2163-2168.